Jove
Visualize
Contact Us

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lonafarnib for chronic hepatitis delta: Clinical mechanism of action, development, and evolving role in combination therapy.

Antiviral research·2026
Same author

Hepatitis C elimination: is it time to redefine the goals?

Nature reviews. Gastroenterology & hepatology·2026
Same author

The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view.

Nature reviews. Gastroenterology & hepatology·2026
Same author

Cost of hepatic decompensation and liver transplantation events in primary biliary cholangitis: a retrospective observational study.

Journal of comparative effectiveness research·2026
Same author

Protecting the future generation through science and HBV vaccination.

Hepatology (Baltimore, Md.)·2025
Same author

Impact of Double Reflex Testing and Linkage to Treatment on Clinical Outcomes of Chronic Hepatitis Delta Virus Infection in the United States.

Journal of viral hepatitis·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 16, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Improving outcomes for patients with chronic hepatitis B.

Robert G Gish1

  • 1Department of Medicine, Division of Hepatology and Complex GI, Physicians Foundation, California Pacific Medical Center, 2340 Clay Street, Room 223, San Francisco, CA 94115, USA. gishr@sutterhealth.org

Current Gastroenterology Reports
|March 6, 2007
PubMed
Summary

Managing chronic hepatitis B (CHB) aims to prevent liver cancer and failure. Effective treatments, including new oral antivirals and vaccines, significantly improve long-term patient outcomes.

More Related Videos

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

Related Experiment Videos

Last Updated: Jul 16, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

Area of Science:

  • Hepatology
  • Virology
  • Public Health

Background:

  • Chronic hepatitis B (CHB) poses a significant global health risk, potentially leading to cirrhosis and hepatocellular carcinoma.
  • Long-term patient outcomes in CHB are strongly correlated with serum levels of hepatitis B virus DNA.
  • Reducing HBV-related mortality and liver transplantation necessitates active intervention and vaccination strategies.

Purpose of the Study:

  • To review current strategies for improving long-term outcomes in patients with chronic hepatitis B.
  • To discuss the role of vaccines, interferon, and various oral antiviral agents in managing CHB.
  • To highlight advancements in CHB treatment and their impact on disease progression and survival.

Main Methods:

  • Review of large-scale studies and clinical trials on CHB management.
  • Analysis of data on the efficacy of antiviral treatments, including oral medications and pegylated interferon.
  • Examination of the impact of interventions on HBV DNA levels, histology, seroconversion, and clinical outcomes.

Main Results:

  • New oral antiviral treatments offer potent antiviral effects, good tolerability, and minimal resistance, leading to improved histology and stable seroconversion.
  • Long-term use of oral medications has been associated with reduced incidence of liver cancer, disease reversal, and progression to liver failure.
  • Pegylated interferon therapy has shown modest rates of hepatitis B e antigen seroconversion and histological improvements.

Conclusions:

  • Vaccination and active intervention are crucial for decreasing the global burden of HBV infection.
  • Modern oral antiviral therapies represent a significant advancement in CHB management, improving long-term prognosis.
  • A combination of therapeutic strategies, including newer agents, is essential for optimizing patient outcomes and preventing severe liver disease complications.